Global Proteomic Profiling of Pediatric AML: A Pilot Study
Open Access
Abstract
Acute Myeloid Leukemia (AML) is a heterogeneous disease with several recurrent cytogenetic abnormalities. Despite genomics and transcriptomics profiling efforts to understand AML’s heterogeneity, studies focused on the proteomic profiles associated with pediatric AML cytogenetic features remain limited. Furthermore, the majority of biological functions within cells are operated by proteins (i.e., enzymes) and most drugs target the proteome rather than the genome or transcriptome, thus, highlighting the significance of studying proteomics. Here, we present our results from a pilot study investigating global proteomic profiles of leukemic cells obtained at diagnosis from 16 pediatric AML patients using a robust TMT-LC/LC-MS/MS platform. The proteome profiles were compared among patients with or without core binding factor (CBF) translocation indicated by a t(8;21) or inv(16) cytogenetic abnormality, minimal residual disease status at the end of the first cycle of chemotherapy (MRD1), and in vitro chemosensitivity of leukemic cells to cytarabine (Ara-C LC50). Our results established proteomic differences between CBF and non-CBF AML subtypes, providing insights to AML subtypes physiology, and identified potential druggable proteome targets such as THY1 (CD90), NEBL, CTSF, COL2A1, CAT, MGLL (MAGL), MACROH2A2, CLIP2 (isoform 1 and 2), ANPEP (CD13), MMP14, and AK5.Keywords
Funding Information
- National Cancer Institute (R01CA132946)
This publication has 55 references indexed in Scilit:
- Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cellsBlood, 2020
- Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemiaBlood Advances, 2020
- Proteomics Versus Clinical Data and Stochastic Local Search Based Feature Selection for Acute Myeloid Leukemia Patients’ ClassificationJournal of Medical Systems, 2018
- Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemiaJournal of Proteomics, 2018
- Molecular Profiling of High-Risk Pediatric Acute Myeloid LeukemiaBlood, 2016
- The genomic landscape of core-binding factor acute myeloid leukemiasNature Genetics, 2016
- Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to RelapseCancer Research, 2016
- Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapyAmerican Journal of Hematology, 2014
- Childhood and adolescent cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Gene expression profiling of pediatric acute myelogenous leukemiaBlood, 2004